A prior study suggested that overexpression of Twist-1 in EGFR-mutated NSCLC cells was associated with Osimertinib resistance and that inhibition of Twist-1 could be a novel strategy to overcome Osimertinib resistance [4,34,35]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.